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Purpose: To identify the gene causing a severe form of progressive autosomal recessive cone-rod dystrophy presenting
as Stargardt disease and to characterize clinical features in a large American family.
Methods: We characterized an American family who had an unusual retinal dystrophy with clinical features of Stargardt
disease and severe progressive cone-rod dystrophy. Family members underwent complete ocular examinations with
evaluation of visual acuity, visual fields, fundus examination, fluorescein angiography, and electroretinography. Genome-
wide linkage analysis of the family was performed using 408 microsatellite markers spanning the entire human genome.
Direct DNA sequence analysis was used for mutational analysis of the ABCA4 gene in all exons and exon-intron boundary
regions and for testing cosegregation of the mutations with the disease in the family. DNA sequence analysis was used to
determine the presence of the mutations in 200 unrelated controls.
Results: The proband presented with a clinical phenotype that was initially compatible with Stargardt disease, only to
progress to a severe cone-rod dystrophy over the course of a few years. The disease-causing gene in the family was linked
to the ABCA4 locus on chromosomal 1p22. One novel mutation, c.655A>T, was identified in exon 6 and another novel
splicing mutation, c.5312+3A>T, was identified in intron 37 of ABCA4. The mutations were not present in 200 controls.
The two affected sisters in this pedigree were compound heterozygotes for the mutations. Unaffected family members
either did not carry either or had only one of the two mutations.
Conclusions: We have identified two novel ABCA4 mutations, c.655A>T and c.5312+3A>T. When present as a compound
heterozygous state, the mutations cause a phenotype of retinal dystrophy that initially manifests as Stargardt disease and
slowly progresses to a severe cone-rod dystrophy. These results expand the wide range of clinical manifestations of ABCA4
mutations.
Stargardt disease is the most common type of hereditary
macular dystrophy. It is characterized by decreased central
vision, atrophy of the macula and underlying retinal pigment
epithelium, and the frequent presence of prominent flecks in
the posterior pole of the retina. To date, mutations in three
genes  have  been  identified  as  causing  Stargardt  disease,
including  ATP-binding  cassette,  subfamily  A,  member  4
(ABCA4), elongation of very long chain fatty acids-like 4
(ELOVL4),  and  cyclic  nucleotide-gated  channel,  beta-3
(CNGB3)  [1-3].  A  fourth  locus  for  Stargardt  disease  was
mapped to chromosome 4p [4], but the specific gene has not
been identified yet.
The ABCA4 gene encodes a retinal-specific ATP-binding
cassette transporter (ABCR) with 2,273 amino acid residues
and a molecular weight of 220 kDa [5]. The ABCR protein is
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mainly expressed in the outer segment disks of rods and cones
and involved in the transport of retinoid derivatives across the
outer segment disk membrane [6-8]. ABCR may also act in
the visual cycle to flip retinal pigment epithelium all-trans-
retinal adducts from the lumenal to the cytosolic face of the
disk  membrane,  move  free  all-trans-retinal  from  the  lipid
phase of the disk membrane to a juxtamembrane location, or
possibly reorient all-trans-retinal in the bilayer [9,10].
Mutations in ABCA4 are responsible for almost all cases
of classic Stargardt disease. ABCA4 mutations have also been
identified  in  fundus  flavimaculatus,  cone-rod  dystrophy,
retinitis pigmentosa, and age-related macular degeneration
[11-15]. To explain the wide spectrum of vision disorders
caused by mutations in ABCA4, Maugeri et al. proposed that
mutant  alleles  with  severe  consequences  (null  mutations)
cause visual disorders with severe clinical features, while mild
mutations lead to mild clinical phenotypes [16].
We characterized a family with an interesting phenotype
of retinal dystrophy that started as classic juvenile Stargardt
disease,  but  rapidly  progressed  to  a  severe  cone-rod
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638dystrophy. Linkage analysis mapped the disease-causing gene
to  chromosome  1p22  where  ABCA4  is  located.  Sequence
analysis of all 50 exons and exon-intron boundaries in the
ABCA4 gene identified two novel compound heterozygous
mutations:  one  nonsense  mutation  and  one  splicing  site
mutation. The mutations cosegregated with affected members
in the family and were not present in 200 normal controls.
METHODS
Subjects:  A  12  member  Caucasian  family  with  Stargardt
disease was identified in Ohio and characterized at the Cole
Eye  Institute.  Controls  for  this  study  were  all  Caucasian
individuals with an average age range of 53.5±12.1 years and
without  apparent  ophthalmic  problems  by  physical
examinations. Each study participant donated blood samples
(5–20 ml), which were used for isolation of genomic DNA
using the DNA Isolation Kit for Mammalian Blood (Roche
Diagnostic Co., Indianapolis, IN). This study was approved
by the Institutional Review Board on Human Subjects of the
Cleveland Clinic, and informed consent was obtained from
every participating family member.
Molecular studies: Genome-wide genotyping was performed
by the genotyping service at Marshfield Clinic Center for
Medical Genetics (Marshfield, WI) with 408 microsatellite
markers spanning the entire human genome by every 10 cM.
For fine mapping, six new markers were selected from the
University  of  California  Santa  Cruz  Genome  Browser
database: D1S1588, D1S1170, D1S406, D1S1174, D1S2651,
and D1S2726. Genotyping at these markers were performed
using one fluorescence-labeled (D1S406) marker and five
32P-labeled  polymorphic  markers.  For  the  fluorescence-
labeled  marker,  polymerase  chain  reaction  (PCR)  was
performed in an ABI 9700 PCR system (Applied Biosystems,
Foster City, CA) in a volume of 10 ul containing PCR buffer,
dNTPs,  PCR  primers,  human  genomic  DNA,  and  Taq
polymerase. PCR conditions were: denaturing at 95 °C for 12
min followed by 10 cycles of 95 °C for 15 s, 55 °C for 15 s
and 72 °C for 30 s, then 20 cycles of 89 °C for 15 s, 55 °C for
15 s and 72 °C for 30 s followed by 10 min at 72 °C. After
PCR, 100 µl water was added into each reaction well of PCR
product and 2 µl was drawn out into a new well. Next, a mix
of 12 µl formamide and 0.5 µl ROX size standards was added
to each well. A ROX size standard (Applied Biosystems) is a
dye-labeled size standard for the reproducible sizing analysis
for fragments between 35 and 500 bp. The standard contains
16 dye-labeled, single-stranded DNA fragments. The samples
were then analyzed on an ABI 3100 genetic analyzer (Applied
Biosystems).  Results  were  analyzed  with  GeneMapper
software (version 1.1, Applied Biosystems).
For  32P-labeled markers, PCR was carried in a 10 ul
reaction  containing  buffer,  dNTP  mix,  32P-labeled  marker
primers, Taq polymerase, and human genomic DNA. This
Figure 1. Typical retinal phenotype in
affected  members  A:  Left  fundus  of
proband showing temporal optic nerve
pallor, attenuated retinal blood vessels,
macular  pigmentary  and  atrophic
changes,  and  some  fine  pigment
clumping outside the vascular arcade.
B: Mid-transit fluorescein angiogram of
left fundus of younger sister reveals a
dark  choroid  sign  with  some  retinal
pigment epithelium (RPE) transmission
defects in a perifoveal distribution. C
and  D:  Right  and  left  fundus
photographs of younger sister at age 12
years show mottling of RPE in macular
region  but  no  flagrant  pigmentary
changes; there is slight temporal pallor
of the optic nerve heads, especially in
left eye.
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639mixture was placed in a thermocycler for 5 min of denaturing
at 95 °C followed by 30 cycles of 95 °C for 30 s, 55 °C for 30
s, and 72 °C for 30 s and a final extension step at 72 °C for 10
min.  PCR  products  were  separated  on  6%  denaturing
polyacrylamide gels, and alleles were called manually.
Mutational  analysis  was  performed  by  direct  DNA
sequence  analysis.  Each  exon  and  flanking  exon-intron
sequences were PCR-amplified using the standard conditions
with  specific  primers  (Appendix  1).  PCR  products  were
purified using Qiaquick gel extraction kit (Qiagen, Valencia,
CA) and sequenced. Sequencing reactions were carried using
Big-Dye  terminator  v1.1  cycle  sequencing  kit  (Applied
Biosystems)  and  analyzed  on  Genetic  Analyzer  3100
(Applied Biosystems). The splicing mutation was confirmed
by  subcloning  PCR  products  from  the  proband  into  the
pcDNA3.1-TOPO vector (Invitrogen, Carlsbad, CA). After
transformation into E. coli DH5α, eight colonies were picked,
and the inserts were PCR amplified and sequenced. Direct
DNA  sequence  analysis  of  exons  where  mutations  were
identified was used to determine whether the mutations were
present in 200 controls.
RESULTS
The proband (II-1) was an eight and a half year-old girl who
presented  with  progressive  reduction  of  vision  of  several
months duration. She had eight siblings who had no ocular
problems except for her youngest sister (II-10), who had a
severe  form  of  Goldenhar  syndrome  with  unilateral
microphthalmia. The proband’s visual acuity was 20/200 in
both eyes with a very mild hypermetropic refractive error. She
had no strabismus and had normal stereopsis. The slit-lamp
examination  was  normal  in  both  eyes.  Ophthalmoscopy
showed  subtle  macular  mottling  of  the  retinal  pigment
epithelium without any evident flecks. The fundus periphery
was normal. A fluorescein angiogram was obtained, which
showed a dark choroid sign. There was hyperfluorescence
around  the  macular  area  with  pinpoint  areas  of
hyperfluorescence  in  the  posterior  pole  and  in  the
midperiphery. A clinical diagnosis of Stargardt disease was
Figure 2. Linkage of the Stargardt family to ABCA4. The pedigree structure of a family with Stargardt disease and results from linkage analysis
and fine mapping to the ABCA4 locus are shown. Circles denote females, and squares indicate males. Dark symbols represent affected
individuals with Stargardt disease. Empty symbols are normal individuals. The proband is marked by an arrow. The gray symbol indicates
occurrence of Goldenhar syndrome but not Stargardt disease. Genotyping results for markers D1S1588, D1S1170, D1S406, D1S1174,
D1S1627, D1S2651, and D1S2726 are shown under each symbol. Haplotypes were constructed on the basis of the minimum number of
recombinations between markers. The disease haplotype shared by all affected individuals is denoted by the blackened vertical bar, and normal
haplotype is denoted by an empty vertical bar. The pedigree information is as in this figure. The proband is marked by an arrow.
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640made. One year later, visual acuity had decreased to 12/200,
and macular pigmentary changes were evident. Individual
II-4, the proband’s younger sister by three years, presented
with vision loss at about the same age as the proband and was
also diagnosed with Stargardt disease.
The proband’s vision continued to deteriorate slowly, and
she developed temporal pallor of her optic nerve head as well
as peripheral pigmentary changes in a bony spicule pattern
(Figure  1A).  She  also  developed  a  fine  nystagmus.  Her
macular areas took on a beaten bronze appearance. At the age
of 15 she complained of significant difficulties with dark
adaptation.  An  electroretinogram  showed  no  recordable
waveforms under scotopic and photopic conditions. At the age
of 17 her visual acuity was 20/500 OD and 4/200 OS. The
peripheral pigmentary changes had become extensive, and her
visual fields showed severe peripheral constriction.
Family member II-4 had a similar clinical course with
minor differences. She had a similar level of visual acuity.
There was a dark choroid sign on angiography (Figure 1B).
Her  photopic  and  scotopic  electroretinographic  responses
were  recordable  but  reduced  by  about  50%  in  amplitude.
When she was last examined at the age of 14 years, she had
not  developed  peripheral  pigmentary  changes,  but  rather
depigmented spots she had in the fundus midperiphery. Her
macular areas were atrophic (Figure 1C,D). Her last visual
acuity was 20/450 OD and 2/200 OS.
The  inheritance  pattern  in  the  family  appeared  to  be
autosomal recessive (Figure 2). The parents had normal eye
examinations  and  were  not  consanguineous.  Due  to  the
moderate size of the family, we performed a genome-wide
genotyping scan to identify the chromosomal location of the
disease-causing  gene  in  the  family.  A  total  of  408
microsatellite markers that covered the entire human genome
by  every  10  cM  were  analyzed.  A  positive  linkage  was
identified with marker D1S1627 on chromosome 1 (position,
106,765,188 bp). Six additional markers flanking D1S1627
were  selected  for  fine  mapping.  As  shown  in  Figure  2,
haplotype analysis showed that the two affected individuals
(II-1 and II-4) carried haplotype 2–1–2–2–1–1–2 from the
father and haplotype 1–1–3–1–3–2–3 from the mother. None
of  the  other  siblings  carried  both  haplotypes.  Analysis  of
recombinant events defined the location of the disease gene
above D1S2651.
The ABCA4 gene (position, 94,239,702–94,249,073 bp)
is located within the locus and became a strong candidate gene
Figure  3.  Identification  of  two  novel
ABCA4  mutations.  DNA  sequence
analysis  for  patient  II-1  showed  the
presence of compound heterozygous c.
655A>T and c.5312+3A>T mutations.
A and D show the sequences from a
normal  and  affected  family  member
with  mutation  c.655A>T  allele,
respectively.  B  and  E  show  the
sequences from a normal and affected
family  member  with  mutation  c.
5312+3A>T allele, respectively. C and
F show sequences for the wild type and
mutant  c.5312+3A>T  allele,
respectively, which were separated by
subcloning  of  PCR  products  from  an
affected family member.
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641responsible for the phenotype in the family. PCR primers were
designed to amplify and sequence all exons and exon-intron
boundaries of the ABCA4 gene. Two novel mutations were
identified (Figure 3). An A to T change in exon 6 (c.655A>T)
resulted in a stop codon and thus generated a mutant ABCR
protein (p.R219X; Figure 3A for wild type and Figure 3D for
mutant sequence). The other mutation of A to T change (c.
5312+3A>T) was identified at a 5′ splicing site in intron 37
(Figure 3B for wild type and Figure 3E for mutant sequence).
For confirmation of the splicing mutation, PCR products were
cloned  and  multiple  clones  were  sequenced.  Mutation  c.
5312+3A>T was confirmed (Figure 3C showing wild type and
Figure 3F showing mutant, both from cloned PCR products).
The substitution of A with T will abolish the splicing site as
demonstrated by analysis with NetGene2. The mutation was
predicted  to  introduce  intron  37  into  the  mature  ABCA4
mRNA  during  post-transcriptional  splicing  and  cause  a
frameshift. The predicted mutant protein would have 1–1770
amino acid residues of ABCR followed by seven exogenous
amino acid residues (LAVWAIS) that are translated from the
sequence of intron 37. Amino acid residues 1771–2273 of
ABCR would be deleted in the mutant protein.
Direct DNA sequence analysis was used to determine
whether the mutations cosegregate with the disease in the
family. As shown in Figure 4, only the two affected siblings
carried  both  mutations,  c.655A>T  from  the  father  and  c.
5312+3A>T from the mother. Thus, the affected individuals
are compound heterozygotes for both mutations. However,
the normal family members carried only one or neither of the
two mutations. These two mutations were not found in 200
unrelated controls by direct DNA sequence analysis.
DISCUSSION
In this study, we identified two novel compound heterozygous
mutations, c.655A>T and c.5312+3A>T, in the ABCA4 gene
that  cause  autosomal  recessive  Stargardt  disease  in  an
American family. The two mutations cosegregated with the
disease  in  the  family  with  two  affected  siblings  being
compound heterozygotes, whereas eight other normal siblings
and  two  parents  carried  only  one  or  neither  of  the  two
mutations. The two mutations were absent in 200 normal
controls. The family showed an uncommon ABCA4-related
phenotype in which affected individuals present with classic
juvenile Stargardt disease, but rapidly progress to show a
severe cone-rod dystrophy clinical phenotype.
The novel compound heterozygous severe mutations may
explain the distinct clinical features observed in the family.
As proposed by Maugeri et al. [16], two null ABCA4 alleles
such  as  homozygous  mutation  IVS30+1G>T  results  in
retinitis pigmentosa; compound heterozygosity for a null and
a  moderately  severe  mutation  such  as  IVS30+1G>T  and
IVS40+5G>A causes cone-rod dystrophy; two moderately
Figure 4. Cosegregation of two novel ABCA4 mutations with the disease in the family. Sequence analysis on mutations c.655A>T and c.
5312+3A>T were done on every family member. Both mutations cosegregated with the disease within the family. Both affected sisters inherited
the c.655A>T mutant allele from their father and the c.5312+3A>T mutant allele from their mother. Normal siblings either carried both
widetype alleles (II-2, 6, 8, 9) or only one mutant allele (II-3, 5, 7, 10).
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642severe  mutations  or  a  mild  and  a  severe  allele  such  as
IVS30+1G>T  and  2588G>C  (a  mild  mutation)  cause
Stargardt disease. In our study, the mutant c.655A>T allele in
exon 6 causes early termination of the protein synthesis. The
truncated protein has 218 residues, which is less than one-
tenth of the wild-type protein. In either case, it will abolish a
functional  ABCR  protein.  In  contrast,  the  c.5312+3A>T
splicing mutation occurs after exon 37, which results in a
mutant ABCR with the first 1,770 amino acid residues (80%
of ABCR) intact and thus may cause a less severe effect on
the function of ABCR. The combined effect of these two
mutations  thus  may  lead  to  the  special  clinical  feature
identified in the family under this study. Most recently Ben-
Ya’acov et al. [17] studied 15 members of six consanguineous
Arab families who reside in the same village and manifest a
retinal  degeneration  that  seems  identical  to  the  one  we
describe here. During early stages of disease, funduscopic and
angiographic findings as well as retinal function resemble
those  of  Stargardt  disease,  while  later  in  life,  severe,
widespread  cone-rod  degeneration  ensues.  Marked
progressive involvement of the retinal periphery distinguishes
this phenotype from classic Stargardt disease. These authors
found two novel ABCA4 deletions, p.Cys1150del and c.4254–
15del23.  Interestingly,  one  of  their  patients  who  is  a
compound heterozygote for the deletions had typical Stargardt
disease,  while  the  remaining  14  patients,  who  were
homozygous for the c.4254- 15del23 intronic deletion, had the
progressive form of disease. The authors performed detailed
RT–PCR analysis in normal retina and lymphoblastoid cells
and could not find the normal full-length ABCA4 transcript
in lymphoblastoid cells of affected homozygote patients who
only showed alternatively spliced transcripts, indicating that
homozygosity  for  the  novel  c.4254–15del23  splicing
mutation  is  associated  with  a  severe  progressive  form  of
disease. In summary, we characterized a family presenting a
phenotype of progressive transition from Stargardt disease to
severe cone-rod dystrophy. We identified two novel mutations
in the ABCA4 gene as a causal for the disease in the family.
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644Appendix 1. PCR primers for amplifying ABCA4 exons
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1.”  This  will  initiate  the  download  of  a  pdf  archive  that
contains the file.
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